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Objectives This report characterizes a syndrome of granulomatous infiltration presenting as sustained monomorphic ven-
tricular tachycardia (SMVT) with mediastinal adenopathy in patients with preserved ventricular function.
Background Unlike truly idiopathic ventricular tachycardia, SMVT due to granulomatous infiltration responds poorly to radio-
frequency ablation and has a poor prognosis.
Methods Patients without obstructive coronary artery disease and with normal ventricular function presenting with SMVT
other than posterior fascicular morphology were evaluated. Computed chest tomograms, cardiac magnetic
resonance imaging, and 18-fluorodeoxyglucose positron emission tomographic scans (18FDG PET-CT) were
performed. Significant lymph nodes were evaluated for tuberculosis and sarcoidosis. Initial treatment included
antiarrhythmic drugs  radiofrequency ablation. Additionally, patients with evidence of tuberculosis received
anti-tuberculosis therapy; the rest were treated as sarcoidosis.
Results Mediastinal adenopathy with mid-myocardial scar and/or focal myocardial inflammation was observed in 14
patients; lymph nodes revealed noncaseating granulomas in all. Evidence of tuberculosis was present in 79%.
During follow-up (median duration 25 months), SMVT recurred despite initial treatment in 92%. Addition of
disease-specific therapy abolished further recurrences in 64% of them. Decrease in SMVT correlated with resolu-
tion of myocardial inflammation on serial 18FDG PET-CTs. Appropriate therapies occurred in 67% of patients re-
ceiving implantable cardioverter-defibrillators.
Conclusions A subset of patients with SMVT with preserved ventricular function has a syndrome of arrhythmogenic myocardi-
tis with granulomatous mediastinal adenopathy due to myocardial tuberculosis or cardiac sarcoidosis. This entity
is optimally managed with a combination of disease-specific therapy and antiarrhythmic measures. (J Am Coll
Cardiol 2011;58:48–55) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.044t
h
o
tSustained monomorphic ventricular tachycardia (SMVT)
with preserved ejection fraction (EF) typically has a benign
course and responds well to antiarrhythmic drugs (AADs)
and radiofrequency ablation (RFA) (1). We describe the
clinical features, diagnostic and therapeutic strategies, and
follow-up results of a cohort of patients who presented with
SMVT with preserved EF who were found to have tuber-
culosis or sarcoidosis on evaluation; this patient subset
responded poorly to AADs and RFA.
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Patient population. Between January 2008 and June 2009,
of the 29 patients referred to our center with SMVT and the
features listed in Table 1, 19 consented to further evalua-
tion. Sustained monomorphic ventricular tachycardia with
granulomatous mediastinal lymphadenopathy was diag-
nosed in 11 of them (58%). This report describes the course
of these 11 patients and an additional 3 patients diagnosed
between May 2006 and December 2007.
Diagnostic evaluation. Figure 1 summarizes the diagnos-
ic and therapeutic strategy adopted in patients suspected of
aving SMVT due to granulomatous infiltration. The site
f the index ventricular tachycardia (VT) was localized on
he basis of 12-lead electrocardiography as interpreted by 2
bservers. Three or more episodes of sustained VT/day or a
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June 28, 2011:48–55 VT in Granulomatous Diseasesingle episode lasting more than 1 h despite treatment was
defined as a VT storm (2).
IMAGING. All patients underwent contrast-enhanced 64-
slice computed tomograms (Siemens, Erlangen, Germany).
Delayed gadolinium enhancement-cardiac magnetic reso-
nance imaging (DE-CMR) was done with a 1.5-T scanner
(Siemens) in the 11 patients without prior implanted
devices. “Late” enhancement denoting myocardial scar was
sought as previously described (3). A resting positron
emission tomographic study after administration of 18-
fluorodeoxyglucose in conjunction with a computed tomo-
gram (18FDG PET-CT) and a 13N-ammonia cardiac per-
fusion scan was performed on 12 patients, including the 3
who did not undergo a DE-CMR, with a 16-slice scanner
(Siemens) as per a standard protocol (4). High 18FDG
ptake was interpreted as inflammation; matched perfusion
nd metabolism defects were interpreted as scar.
ETIOLOGICAL EVALUATION. The tuberculin skin test for
.tuberculosis was performed with 5 tuberculin units of
urified protein derivative. Horizontal induration of 10
m at 48 h was considered positive. Lymph nodes were
ampled in all, as per the described protocol (Fig. 1).
ndomyocardial biopsy was performed in 4. All tissue
amples were subjected to histopathology, Gram’s stain, and
taining and culture for mycobacteria and fungi. A deoxy-
ibonucleic acid polymerase chain reaction (PCR) detecting
he IS6110 sequence of M.tuberculosis was performed on 9
of the tissue samples.
Treatment. INITIAL THERAPY. All patients received AADs
beta-blockers and amiodarone) as initial therapy, with
dditional intravenous lidocaine/oral Mexiletine being used
o control breakthrough episodes of arrhythmia. RFA was
erformed in 5 as part of initial therapy, predominantly
mong the earlier patients. Mapping was performed with an
lectroanatomic system (CARTO, Biosense Webster, Dia-
ond Bar, California); a Stockert RF generator (Stockert
mBh, Freiburg, Germany) and an 8-F 3.5-mm tip irri-
ated catheter (NAVISTAR, Biosense Webster) were used
or ablation. Successful RFA was defined as noninducibility
f SMVT on ventricular stimulation from 2 sites including
extrastimuli; stimulation was performed without drugs
nd during continuous infusion of isoprenaline to a maximum
ose of 6 g/min. Implantable cardioverter-defibrillators
ICDs) were recommended in all; however, owing to
nancial constraints, only 9 received ICDs.
DISEASE-SPECIFIC THERAPY. Disease-specific therapy for tu-
berculosis or sarcoidosis was added to initial therapy in all
patients as per the protocol in Figure 1. Individualized titration
of disease-specific therapy was guided by clinical response and
serial 18FDG PET-CTs. Treatment duration ranged from 12
o 30 months. A 3-month period was allowed for disease-
pecific therapy to take effect, after which its effect was
nalyzed. Specific therapy was delayed due to late diagnosis inof the initial patients; this helped
o assess the impact of disease-
pecific therapy.
ollow-up. Patients were evalu-
ted at 3 monthly intervals and
uring symptomatic recurrence.
nterrogation of ICD and 12-
ead electrocardiograms were per-
ormed at each evaluation. One
atient was lost to follow-up af-
er 1 month.
tatistical methods. Continu-
us variables were reported as
ean  SD or medians (with
nterquartile range), as appropri-
te. Significance of differences
as estimated with a Wilcoxon
atched-pairs signed-rank test.
he Pearson’s test was used to
orrelate post-treatment change
n VT frequency with resolution of
nflammation on 18FDG PET-
CT. The patient who was lost to
follow-up was excluded from all
outcome analyses.
Results
Baseline characteristics. Baseline and follow-up features
are summarized in Table 2. The mean age at presentation
was 44  11 years; mean left ventricular EF was 58  6%.
None of the patients had symptoms of extracardiac disease.
No patient had atrioventricular conduction block. Median
follow-up was 25 months (interquartile range: 15 to 58
months).
VT morphology. All of the patients presented with
SMVT. Morphologies of the index and subsequent VTs did
not conform to any particular pattern (Table 2). The
majority of the recurrent VTs (78%, or 7 of 9 recurrences
where 12-lead electrocardiograms were available) had a
different morphology, as compared with the index VT.
VT recurrence. Sustained monomorphic ventricular tachy-
cardia recurred at a median follow-up of 4 months (range
0.6 to 9 months) in 12 of 13 patients. Eleven of these
patients had recurrence of VT before effective disease-
Features of Patients Evaluated for Monomorphic VTWith Mediastinal Adenopathy Due to GranulomatousInfil ration
Table 1
Fe tures of Pati nts Evaluated for M nomorphic VT
With Mediastinal Adenopathy Due to
Granulomatous Infiltration
Normal biventricular systolic function (ejection fraction 50%)
Absence of obstructive coronary artery disease
Absence of known ion channelopathies causing VT
Absence of transient, reversible causes of VT like electrolyte abnormalities
1 episode of sustained monomorphic VT of any morphology other than typical
left ventricular posteroseptal fascicular morphology, defined as VT of right
bundle branch block morphology, superior axis, and QRS duration 140 ms
Abbreviations
and Acronyms
18FDG PET-CT  18-
fluorodeoxyglucose positron
emission tomography with
computed tomogram
AAD  antiarrhythmic drug
ATT  anti-tuberculosis
therapy
CS  cardiac sarcoidosis
DE-CMR  delayed
gadolinium-enhancement
cardiac magnetic
resonance imaging
EF  ejection fraction
ICD  implantable
cardioverter-defibrillator
PCR  polymerase chain
reaction
RFA  radiofrequency
ablation
SMVT  sustained
monomorphic ventricular
tachycardia
VT  ventricular
tachycardiaVT  ventricular tachycardia.
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VT in Granulomatous Disease June 28, 2011:48–55Figure 1 Diagnostic and Therapeutic Strategy in Patients Suspected of Having SMVT Due to Granulomatous Disease
AFB  acid fast bacilli; CAD  coronary artery disease; DE-CMR  delayed gadolinium enhancement-cardiac magnetic resonance imaging; DNA-PCR  DNA-based poly-
merase chain reaction; 18FDG PET-CT  18fluorodeoxyglucose positron emission tomography with computed tomogram; FNAC  fine needle aspiration cytology; HRCT 
contrast-enhanced high resolution computed tomogram of the chest; ICD  implantable cardioverter-defibrillator; LV  left ventricular; MMVT  monomorphic ventricular
tachycardia; PCR  polymerase chain reaction; RFA  radiofrequency ablation; SMVT  sustained monomorphic ventricular tachycardia; USG  ultrasonography;
VATS  video-assisted thoracoscopic surgery; VT  ventricular tachycardia.
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June 28, 2011:48–55 VT in Granulomatous Diseasespecific therapy. Overall, there were 117 recurrences during
58.2 patient years of follow-up, including 18 VT storms.
Myocardial scarring and inflammation. Myocardial scar-
ring or focal myocardial hypermetabolism was present in all
(Fig. 2). DE-CMR revealed mid-myocardial scars in 9 of 11
patients (82%) (Fig. 3A); overall, when defined by either
DE-CMR or single-photon emission computed tomography–
PET, scar was present in 10 (71%). 18FDG PET-CT revealed
myocardial inflammation in 11 of 12 (92%) (Fig. 3B). The only
patient without myocardial uptake on 18FDG PET-CT had a
iffuse matched perfusion-metabolism defect; etiological eval-
ation was delayed by several years in this patient. Myocardial
car in the absence of inflammation was the cause of VT in this
atient. In contrast, 2 patients with normal DE-CMRs had
yocardial inflammation in the absence of scar.
xtracardiac involvement. 18FDG avid mediastinal nodes
ere present in all, including the patient without myocardial
nflammation. Six patients had additional extramediastinal
denopathy (Table 2). Computed tomography scan showed
symptomatic pulmonary parenchymal abnormalities con-
istent with sarcoidosis in 2 patients.
istopathologic analysis. Multiple noncaseating epitheli-
id granulomas consistent with either sarcoidosis or tuber-
ulosis were present in 13 of the 14 lymph node samples
1 sample was inadequate). Endomyocardial biopsy was
ormal in 3 patients and showed nongranulomatous, non-
Figure 2 Sites of Myocardial Scar and/or Inflammation Among
Scar was defined as delayed gadolinium enhancement on cardiac magnetic resona
emission tomographic computed tomography scan (PET) metabolism defect. Increa
scar and/or focal myocardial inflammation. *Matched metabolism - perfusion defe
ventricle; LV-AW  anterior wall of the left ventricle; LV-IW  inferior wall of the le
ventricle; RV  right ventricle; RVOT  right ventricular outflow tract; sl. no.  seraseating myocardial necrosis in the fourth.uberculosis as an underlying etiology. Skin test for
uberculosis was positive in 11 of 14 patients (79%). Three
atients showed an exuberant, necrotic local reaction to the
urified tubercular protein derivative. Lymph node biopsy
as positive for M.tuberculosis deoxyribonucleic acid PCR in
of 9 patients. M.tuberculosis was cultured from the lymph
ode in 2 patients (Table 2).
lectrophysiological study and RFA. Sustained mono-
orphic ventricular tachycardia was inducible in 4 of 5
atients. Two morphologies of SMVT were inducible in 2
f them. Induced VTs were consistent with a re-entrant
echanism in 2 and focal mechanism in 2; the mechanism
ould not be determined in 2 of the VTs. Low voltage areas
bipolar voltage 1.5 mV) on substrate map and sites of
FA corresponded to the sites of scar in DE-CMR or to
he site of inflammation in 18FDG PET-CT (Table 3).
Response to treatment. RFA was successful in 3 of the 5
patients who received it as part of initial therapy. Before
effective disease-specific therapy, VT recurred in 100% of the
patients who received AADs with RFA as initial therapy and
in 75% of patients who received AADs only. Among the 11
patients who experienced recurrence while receiving initial
therapy, disease-specific therapy controlled the VT in 9 (82%).
This included 7 patients (64%) in whom further VT was
abolished and 2 others (18%) in whom VT frequency de-
creased. Overall, disease-specific therapy reduced the VT
nts With Granulomatous Myocarditis
aging (MRI) or matched 13N-ammonia perfusion/18fluorodeoxyglucose positron
8FDG uptake on PET-CT indicated inflammation. All patients had mid-myocardial
gestive of scar was present on PET. IVS  interventricular septum; LV  left
ricle; LV-LW  lateral wall of the left ventricle; LV-PW  posterior wall of the left
ber.Patie
nce im
sed 1
ct sug
ft vent
ial numfrequency from 6.5 VTs/patient-year to 0.6 VTs/patient-year
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VT in Granulomatous Disease June 28, 2011:48–55(p  0.016) (Fig. 4); 16 VT storms occurred before effective
disease-specific therapy, compared with 2 after. Reduction in
VT burden correlated with resolution of myocardial inflam-
mation on post-treatment 18FDG PET-CTs (r 0.87). This
esponse was observed among all disease-specific therapy pro-
ocols (Fig. 5). Appropriate ICD therapies occurred in 6 of 9
CD recipients (67%). One patient who was diagnosed late
eveloped biventricular dysfunction before etiological diagnosis
nd succumbed to progressive heart failure.
iscussion
his report describes a cohort of patients wherein a granu-
omatous disease presented as SMVT with preserved EF.
Figure 3 Demonstrations of Myocardial Scar and Inflammation
(A) Demonstration of myocardial scar. Delayed gadolinium enhanced cardiac magn
characteristic mid-myocardial scar (arrows) in the interventricular septum. Owing t
(B) Demonstration of myocardial inflammation. The 18fluorodeoxyglucose (FDG) po
A showing myocardial hypermetabolism in the anterior and lateral walls, basal sepecurrent VT of morphology different from the indexresentation should arouse suspicion of an underlying infil-
rative disorder among such patients.
iagnosis of cardiac sarcoidosis. Some of our patients
annot be diagnosed to have cardiac sarcoidosis (CS) on the
asis of the Japanese Ministry of Health criteria (5,6). How-
ver, patchy mid-myocardial scar, focal intense myocardial
18FDG uptake, noncaseating granulomas in lymph nodes, and
the observed treatment response are all consistent with CS
(4,6). We recommend a protocol of routine contrast-enhanced
chest computed tomography scans followed by sampling of the
involved nodes as the preferred strategy for histological diag-
nosis. Over-reliance on endomyocardial biopsies might have
esonance imaging (from patient number 7 in Table 2 and Figure 2) showing the
atchy nature, the scar does not enhance as intensely as an ischemic scar.
emission tomographic computed tomography scan of the same patient as in
nd a mediastinal lymph node.etic r
o its p
sitron
tum, aunderdiagnosed this entity in the past (7).
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June 28, 2011:48–55 VT in Granulomatous DiseaseUnlike Banba et al. (8), who described VT as a late
manifestation of CS, we found that both the early inflam-
matory and late scar phases of this disease could cause
SMVT, as evidenced by: 1) myocardial inflammation with-
out scar in 2 patients, and scar without inflammation
causing SMVT in another; and 2) resolution of inflamma-
tion on 18FDG PET-CT correlating with reduction in VT
burden.
CS versus myocardial tuberculosis. Isolation of M.tuber-
ulosis in 2 of our patients and their response to ATT
onfirms isolated myocardial tuberculosis presenting as
MVT, a rare but described entity (9). Whether M.tuber-
ulosis PCR positivity in sarcoid granulomas has an etiolog-
cal implication is a matter of debate (10). Tuberculin skin
est positivity has been used to differentiate tuberculosis
rom sarcoidosis; whether this observation can be extended
o isolated CS is unexplored (11). From a therapeutic
erspective, administering immunosuppressants without
oncomitant ATT to such patients could result in flare-up
f tuberculosis. This underscores the importance of evalu-
tion for tuberculosis among these patients.
reatment considerations. Unlike usual forms of SMVT
ith preserved EF, those due to granulomatous myocarditis
esponded poorly to RFA and had a 100% recurrence rate,
finding similar to that reported by Koplan et al. (12).
ppropriate therapies occurred in 67% of ICD recipients.
ddition of disease-specific therapy significantly decreased
T burden and nearly eliminated VT storms. We recom-
end a combination of disease-specific therapy, AADs, and
CD rather than RFA as the first line of treatment for
MVT with preserved EF due to granulomatous
Figure 4 Change in VT Frequency After Addition of Disease-
Specific Therapy to Antiarrhythmic Drugs/RFA
In the 13 patients available to follow-up, the effect of disease-specific therapy
was measured starting from 3 months after its initiation. Mean follow-up
before effective disease-specific therapy was 37  53 months and after effec-
tive therapy was 16  13 months. Effective disease-specific therapy caused a
significant (p  0.05) decrease in ventricular tachycardia (VT) burden. RFA 
radiofrequency ablation.myocarditis.Ba T
P S
1
8
FD
ca
rd
po
ly
ve
nt
emission tomographic computed tomography scan; IVS  interventricular septum; IW  inferior wall of the left ventricle; LV  left ventricle; LW  lateral wall of the left ventricle; RFA  radiofrequency
ablation; RVOT  right ventricular outflow tract.
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VT in Granulomatous Disease June 28, 2011:48–55Figure 5 Pre- and Post-Treatment 18FDG PET-CT Scans Showing Resolution of Inflammation With Treatment
(A) 18Fluorodeoxyglucose positron emission tomographic computed tomography scan (18FDG PET-CT) images showing high myocardial and mediastinal node (white
arrows) uptake at baseline which resolved after treatment with anti-tuberculosis therapy in a patient with a positive M. tuberculosis culture from the mediastinal node.
(B) 18FDG PET-CT images showing high myocardial, mediastinal, and splenic (white arrows) uptake at baseline which resolved after treatment with corticosteriods and
methotrexate in a patient with a negative acid fast bacilli stain, culture, M. tuberculosis DNA-polymerase chain reaction, and a negative tuberculin skin test.EPS/RFA Findings of Patients Undergoing RFA, Correlated With DE-CMR and 18FDG PET-CT FindingsTable 3 EPS/RFA Findings of Patients Undergoing RFA, Correlated With DE-CMR and 18FDG PET-CT Findings
Patient Serial #
1 7 8 10 12
Site of scar in DE-CMR None IVS IVS, AW, IW, LW IVS, RVOT RVOT
Site of inflammation in 18FDG PET-CT IVS IVS, AW, LW Not done IVS, LW AW, IW, LW, LV apex
Site of low voltage None IVS IVS LW RVOT
Site of RFA IVS/RVOT septum IVS IVS LW RVOT
Patient serial # correspond to Table 2 and Figure 2.
AW anterior wall of the left ventricle; DE-CMR delayed gadolinium enhanced cardiac magnetic resonance imaging; EPS electrophysiological study; 18FDG PET-CT 18fluorodeoxyglucose positron
11
1
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June 28, 2011:48–55 VT in Granulomatous DiseaseStudy limitations. This is a predominantly retrospective
analysis performed on a small number of patients from an
area endemic to tuberculosis. The report highlights the
effect of specific therapy in myocardial tuberculosis and
describes only a limited number of patients with CS.
Etiological factors might vary in different areas; however,
work-up for various granulomatous disorders is warranted in
this entity. Larger, prospective studies are required to clarify
the relative diagnostic importance of the various findings we
have observed.
Conclusions
A subset of patients with SMVT and preserved EF has
underlying granulomatous inflammation, due to CS or myo-
cardial tuberculosis. Mediastinal adenopathy with mid-
myocardial scar and/or focal myocardial hypermetabolism
characterize this subset. Histopathology of the involved nodes
reveals granulomas. Recurrent arrhythmia is frequent in them,
despite AADs and RFA. Disease-specific therapy tailored to
the underlying disease can reduce and often abolish recurrent
VT. Late recurrences of VT seem to justify ICD insertion.
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